Key Drivers
- Strong margins
- Solid cash flow
- Higher leverage
AIAI Summary
Zoetis should be viewed as a “show-me” stock rather than a reliable steady compounder, because the 2026 guidance reset exposed weaker-than-assumed companion-animal demand and leaves upside dependent on clear vet-traffic stabilization, not just buybacks and high margins.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Solid cash flow
- •Higher leverage
Zoetis combines high, consistent profitability and strong free cash flow with solid liquidity, but elevated leverage and a premium valuation temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Lower drift
- •Rebound failed
- •Range-bound action
Over the last month, ZTS drifted lower into the low-$74s, with buyers repeatedly stepping in near $72.66-$73.50 but rallies stalling below $75.80-$76.00, leaving the stock range-bound with a slight bearish tilt unless it reclaims the mid-$76s.
Rebounded from $72.66 on 2026-08-07 to $75.84 on 2026-08-13, then faded again on 2026-08-14
Sentiment & News
Key News Insights:
- •Class-action risk
- •Companion weakness
- •Discounted valuation
ZTS is contending with a class-action overhang and softer companion-animal demand after a 2026 outlook cut, even as some investors still see value in its strong margins, buybacks, and balance sheet.
The stock's near-term sentiment may stay pressured by litigation and guidance cuts, though valuation support could limit downside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings